By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Loxo Oncology 

1 Landmark Square
Suite 1122
Stamford  Connecticut  06901  U.S.A.
Phone: 203-653-3880 Fax: n/a


Company News
Loxo Oncology (LOXO) Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 ASCO Annual Meeting 5/18/2017 11:18:09 AM
Loxo Oncology (LOXO) Announces FDA Orphan Drug Designation Granted To Larotrectinib For The Treatment Of Solid Tumors With NTRK-Fusion Proteins 5/12/2017 8:49:46 AM
Loxo Oncology (LOXO) Announces Enrollment Of First Patient In Phase I Clinical Trial For Highly Selective RET Inhibitor, LOXO-292 5/10/2017 10:19:14 AM
Loxo Oncology (LOXO) Announces First Quarter 2017 Financial Results 5/9/2017 10:29:38 AM
Loxo Oncology (LOXO) To Announce First Quarter 2017 Financial Results 5/2/2017 10:46:02 AM
Loxo Oncology (LOXO) TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers In AACR Phase 1 Update 4/18/2016 8:31:29 AM
Loxo Oncology (LOXO) Prices Follow-On Offering Of Common Stock 11/12/2015 7:32:09 AM
Loxo Oncology (LOXO) Announces Proposed Public Offering Of Common Stock 11/11/2015 7:55:45 AM
Loxo Oncology (LOXO) Announces Third Quarter 2015 Financial Results And Provides Program Updates 11/10/2015 11:06:55 AM
Loxo Oncology (LOXO) To Present At Upcoming Investor Conferences 11/10/2015 11:04:59 AM